Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Palbociclib in Patients With Non–Small-Cell Lung Cancer With CDKN2A Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study
Eugene Ahn, Pam K. Mangat, Elizabeth Garrett‐Mayer, et al.
JCO Precision Oncology (2020), Iss. 4, pp. 757-766
Open Access | Times Cited: 59

Showing 1-25 of 59 citing articles:

A proteogenomic portrait of lung squamous cell carcinoma
Shankha Satpathy, Karsten Krug, Pierre M. Jean Beltran, et al.
Cell (2021) Vol. 184, Iss. 16, pp. 4348-4371.e40
Open Access | Times Cited: 271
Clinical trial design in the era of precision medicine
Elena Fountzilas, Apostolia M. Tsimberidou, Henry Hiep Vo, et al.
Genome Medicine (2022) Vol. 14, Iss. 1
Open Access | Times Cited: 160
Pembrolizumab in Patients With Metastatic Breast Cancer With High Tumor Mutational Burden: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study
Ajjai Alva, Pam K. Mangat, Elizabeth Garrett‐Mayer, et al.
Journal of Clinical Oncology (2021) Vol. 39, Iss. 22, pp. 2443-2451
Closed Access | Times Cited: 145
Squamous cell lung cancer: Current landscape and future therapeutic options
Sally C. M. Lau, Yuanwang Pan, Vamsidhar Velcheti, et al.
Cancer Cell (2022) Vol. 40, Iss. 11, pp. 1279-1293
Open Access | Times Cited: 96
Signaling pathways and targeted therapies in lung squamous cell carcinoma: mechanisms and clinical trials
Zhenyi Niu, Runsen Jin, Yan Zhang, et al.
Signal Transduction and Targeted Therapy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 91
Molecular tumour boards — current and future considerations for precision oncology
Apostolia M. Tsimberidou, Michael Kahle, Henry Hiep Vo, et al.
Nature Reviews Clinical Oncology (2023) Vol. 20, Iss. 12, pp. 843-863
Closed Access | Times Cited: 61
The role of aberrant DNA methylation in cancer initiation and clinical impacts
Franziska Geissler, Ksenija Nesic, Olga Kondrashova, et al.
Therapeutic Advances in Medical Oncology (2024) Vol. 16
Open Access | Times Cited: 19
CDKN2A loss-of-function predicts immunotherapy resistance in non-small cell lung cancer
Stanley I. Gutiontov, William Tyler Turchan, Liam F. Spurr, et al.
Scientific Reports (2021) Vol. 11, Iss. 1
Open Access | Times Cited: 75
Clinical Utility of CDK4/6 Inhibitors in Sarcoma: Successes and Future Challenges
Jocelyn Y. Hsu, Nathan D. Seligson, John L. Hays, et al.
JCO Precision Oncology (2022), Iss. 6
Open Access | Times Cited: 40
Precision Oncology: Evolving Clinical Trials across Tumor Types
I-Wen Song, Henry Hiep Vo, Ying‐Shiuan Chen, et al.
Cancers (2023) Vol. 15, Iss. 7, pp. 1967-1967
Open Access | Times Cited: 37
CDK4/6 inhibitors in lung cancer: current practice and future directions
Shuoshuo Lv, Jie Yang, Jiayuh Lin, et al.
European Respiratory Review (2024) Vol. 33, Iss. 171, pp. 230145-230145
Open Access | Times Cited: 10
Pertuzumab Plus Trastuzumab in Patients With Colorectal Cancer WithERBB2Amplification orERBB2/3Mutations: Results From the TAPUR Study
R. Gupta, Funda Meric‐Bernstam, Michael Rothe, et al.
JCO Precision Oncology (2022), Iss. 6
Closed Access | Times Cited: 36
Pembrolizumab in Patients With Tumors With High Tumor Mutational Burden: Results From the Targeted Agent and Profiling Utilization Registry Study
Herbert L. Duvivier, Michael Rothe, Pam K. Mangat, et al.
Journal of Clinical Oncology (2023) Vol. 41, Iss. 33, pp. 5140-5150
Closed Access | Times Cited: 21
NCT/DKFZ MASTER handbook of interpreting whole-genome, transcriptome, and methylome data for precision oncology
Andreas Möck, Maria‐Veronica Teleanu, Simon Kreutzfeldt, et al.
npj Precision Oncology (2023) Vol. 7, Iss. 1
Open Access | Times Cited: 17
Limited clinical activity of palbociclib and ribociclib monotherapy in advanced cancers with cyclinD‐CDK4/6 pathway alterations in the DutchDRUPand AustralianMoSTtrials
Laurien J. Zeverijn, Eleonora J. Looze, Subotheni Thavaneswaran, et al.
International Journal of Cancer (2023) Vol. 153, Iss. 7, pp. 1413-1422
Open Access | Times Cited: 14
Loss of CDKN2A/B is a Molecular Marker of High-grade Histology and is Associated with Aggressive Behavior in Acinic Cell Carcinoma
Snjezana Doğan, Bin Xu, Satshil Rana, et al.
Modern Pathology (2023) Vol. 36, Iss. 7, pp. 100150-100150
Closed Access | Times Cited: 13
Pertuzumab Plus Trastuzumab in Patients With Endometrial Cancer With ERBB2/3 Amplification, Overexpression, or Mutation: Results From the TAPUR Study
Eugene Ahn, Michael Rothe, Pam K. Mangat, et al.
JCO Precision Oncology (2023), Iss. 7
Closed Access | Times Cited: 13
Mechanisms and Implications of CDK4/6 Inhibitors for the Treatment of NSCLC
Jinmeng Zhang, Dayu Xu, Yue Zhou, et al.
Frontiers in Oncology (2021) Vol. 11
Open Access | Times Cited: 32
Prognosis of immunotherapy for non-small cell lung cancer with CDKN2A loss of function
Lu Zhao, Xiao Zhou, Hui Li, et al.
Journal of Thoracic Disease (2024) Vol. 16, Iss. 1, pp. 507-515
Open Access | Times Cited: 4
Treatment of IDH-mutant glioma in the INDIGO era
Mathew D. Lin, Alexander C.-Y. Tsai, Kalil G. Abdullah, et al.
npj Precision Oncology (2024) Vol. 8, Iss. 1
Open Access | Times Cited: 4
Detecting gene copy number alterations by Oncomine Comprehensive genomic profiling in a comparative study on FFPE tumor samples
Fabio Bozzi, Elena Conca, M. Silvestri, et al.
Scientific Reports (2025) Vol. 15, Iss. 1
Open Access
Challenges and Obstacles in Applying Therapeutical Indications Formulated in Molecular Tumor Boards
Edoardo Crimini, Matteo Repetto, Paolo Tarantino, et al.
Cancers (2022) Vol. 14, Iss. 13, pp. 3193-3193
Open Access | Times Cited: 18
Cobimetinib Plus Vemurafenib in Patients With Colorectal Cancer WithBRAFMutations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study
Kelsey Klute, Michael Rothe, Elizabeth Garrett‐Mayer, et al.
JCO Precision Oncology (2022), Iss. 6
Closed Access | Times Cited: 18
Biomarker-Driven Oncology Clinical Trials: Novel Designs in the Era of Precision Medicine
Donald C. Moore, Andrew S Guinigundo
Journal of the Advanced Practitioner in Oncology (2023) Vol. 14, Iss. 3, pp. 9-13
Open Access | Times Cited: 10
Olaparib in Patients With Metastatic Prostate Cancer With BRCA1/2 Mutation: Results From the TAPUR Study
Eddy S. Yang, Susan Halabi, Michael Rothe, et al.
JCO Precision Oncology (2023), Iss. 7
Closed Access | Times Cited: 9
Page 1 - Next Page

Scroll to top